Why the study?
Knowledge and evidence regarding venous thromboembolism treatment in patients with cancer are limited, despite high incidence and associated disruptions to cancer therapy and quality of life.
Does rivaroxaban prevent recurrence or aggravation of symptomatic VTE in patients with cancer-associated VTE?
Observational (n=500)
Yes
Does rivaroxaban prevent recurrence or aggravation of symptomatic VTE in patients with cancer-associated VTE?
The PRIMECAST study is a prospective registry designed to evaluate the real-world effectiveness and safety of rivaroxaban for cancer-associated venous thromboembolism in Japan.
Background:The incidence of thromboembolism in patients with cancer is approximately 11%, and the risk of thrombosis in patients with malignant tumors is 6-fold higher than that in healthy persons. Thrombosis not only disrupts the treatment of cancer but also induces deterioration of quality of life (QOL). Knowledge about thrombus treatment is limited, and evidence is scarce. Clarification of the status and safety of venous thromboembolism (VTE) treatment in patients with cancer will contribute to active intervention and improvement of prognosis and QOL. In this study, the therapeutic effects of a non-vitamin K antagonist oral anticoagulant for VTE and the prognosis of cancer after treatment will be examined to establish a therapeutic method for VTE in patients with cancer.
No takes yet. Share an insight, caveat, or question.
Tamura et al. (2019) conducted an observational in Cancer-Associated Venous Thromboembolism (n=500). Rivaroxaban vs. Warfarin was evaluated on Recurrence/aggravation of symptomatic VTE or occurrence/aggravation of symptomatic DVT at 24 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: